Clonal Hematopoiesis More Prevalent in Pediatric Cancer Survivors
Survivors of pediatric cancer have a higher rate of clonal hematopoiesis than their peers at any age, a study suggests.
Sarcoma News
SARCOMA CANCER ADVISOR
Sarcoma News
Location of KIT Mutations Impacts Response to TKIs in Patients With GIST
The location of KIT mutations is associated with response to ripretinib and sunitinib in patients with previously treated GIST, research suggests.
Larotrectinib Bests Standard Care for TRK-Fusion Positive Cancers
Larotrectinib prolongs survival when compared with non-TRK inhibitor standard care in adults with TRK fusion-positive cancers, a study suggests.
Ganitumab Provides No Benefit in Metastatic Ewing Sarcoma
Adding ganitumab to standard chemotherapy does not provide a benefit for patients with metastatic Ewing sarcoma, a phase 3 trial suggests.
AYAs With Hematologic Malignancies Have Higher Risk of Early Death
The risk of early death in AYAs with cancer depends on the type of malignancy they have as well as multiple demographic factors, a study suggests.
Tecentriq Approved for Unresectable or Metastatic Alveolar Soft Part Sarcoma
The approval was based on data from a phase 2 study that included 49 patients with unresectable or metastatic ASPS.
Kaposi Sarcoma Incidence Increasing in Black Men, Decreasing in White Men
The incidence of Kaposi sarcoma is increasing among Black men and decreasing among White men in the United States, a study suggests.
Shorter Regimen of Radiotherapy Safe for Soft Tissue Sarcoma
None of the patients had grade 3 or higher acute radiation toxicity.
MYC Inhibitor Can Stave Off Progression in Patients With Advanced Solid Tumors
In a first-in-human trial of patients with solid tumors, a MYC inhibitor appeared tolerable and enabled nearly half of evaluable patients to maintain stable disease.
Predicting the Risk of Thoracic Soft Tissue Sarcoma After Breast Cancer
There are several factors that may increase the risk of thoracic soft tissue sarcoma in patients with a history of breast cancer.
COVID-19 Vaccination Should Not Interrupt ICI Therapy, Researchers Say
COVID-19 vaccination is safe for cancer patients receiving immune checkpoint inhibitors and should not interrupt therapy, according to researchers.
Treatment Changes May Have Reduced Rates of Invasive Breast Cancer in Childhood Cancer Survivors
The incidence of invasive breast cancer among childhood cancer survivors decreased from the 1970s to the 1990s.
Adding Ifosfamide to MAP Provides No Benefit in High-Grade Osteosarcoma
Phase 3 data do not support adding ifosfamide to adjuvant methotrexate, doxorubicin, and cisplatin in patients with high-grade osteosarcoma.
Improving the Rate of Serious Illness Conversations at Oncology Clinics
Researchers sought to increase the rate of serious illness conversations between clinicians and patients with cancer.
Retevmo Approved for RET-Driven Solid Tumors, NSCLC
The approvals were based on data from the LIBRETTO-001 trial.
Cabazitaxel Appears Active in Advanced Dedifferentiated Liposarcoma
Cabazitaxel demonstrated antitumor activity in patients with previously treated, advanced dedifferentiated liposarcoma in a phase 2 trial.
Cancer Patients With HIV May Not Receive Equitable Treatment
Cancer patients with HIV do not receive curative or palliative care in the same way as their HIV-negative peers.
Trabectedin Improves PFS in Advanced Leiomyosarcoma
Adding trabectedin to doxorubicin doubled the median progression-free survival.
Dinutuximab Plus GM-CSF Falls Short in Recurrent Osteosarcoma
Dinutuximab plus GM-CSF produced a low disease control rate that did not meet a historical benchmark.
Carboplatin Deemed Acceptable Replacement for Actinomycin-D in Ewing Sarcoma
There was no significant difference in overall survival between patients who received actinomycin-D and those who received carboplatin.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...